Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $47 per share, valuing the transaction at approximately $7.8 billion. This acquisition significantly bolsters Lilly’s neuroscience franchise by integrating innovative treatments for sleep disorders and broader neurological conditions.
Strategic Core: Orexin Biology The deal centers on Centessa’s portfolio of orexin receptor 2 (OX2R) agonists. Orexin signaling acts as the brain’s master regulator for the sleep-wake cycle, and its disruption is a primary cause of narcolepsy.
-
Lead Candidate: Cleminorexton has demonstrated a potential best-in-class profile in Phase IIa studies for narcolepsy type 1, type 2, and idiopathic hypersomnia.
-
A Targeted Approach: Unlike traditional stimulants, OX2R agonists directly intervene in the biological “switch” of wakefulness, offering potential applications across neuropsychiatric and neurodegenerative indications, including fatigue and cognitive deficits.
Financial Terms and Timeline:
-
Upfront Cash: Lilly will pay $38.00 per share at closing, totaling roughly $6.3 billion in equity value.
-
Contingent Value Right (CVR): An additional $9.00 per share (approx. $1.5 billion) is tied to regulatory milestones, including FDA approvals for cleminorexton or ORX142 before 2030.
-
Completion: The transaction is expected to finalize in the third quarter of 2026, pending shareholder approval and customary regulatory clearances.
This move underscores Eli Lilly’s aggressive strategy to diversify its portfolio beyond its blockbuster GLP-1 franchise, focusing on high-value neuroscience assets with substantial unmet clinical needs.